Comparing SG&A Expenses: Amgen Inc. vs Geron Corporation Trends and Insights

SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding financial trends is crucial. Amgen Inc. and Geron Corporation, two prominent players, showcase contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023.

Amgen Inc.: Steady Growth

Amgen's SG&A expenses have seen a consistent upward trend, growing approximately 31% over the decade. This reflects their strategic investments in marketing and administration, crucial for maintaining their market leadership.

Geron Corporation: A Rapid Surge

In contrast, Geron Corporation's SG&A expenses have skyrocketed by over 300%, indicating aggressive expansion efforts. This surge, especially notable in recent years, suggests a focus on scaling operations and increasing market presence.

Insights and Implications

These trends highlight differing strategies: Amgen's steady growth versus Geron's rapid expansion. Investors and stakeholders should consider these dynamics when evaluating potential opportunities in the biotech sector.